News and Announcements
Folkestone’s Development Fund Closes Oversubscribed After 1 Week
- Published March 20, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Folkestone Limited is pleased to announce that Folkestone Wollert Development Fund has closed significantly oversubscribed one week after its launch.
KEY TAKEAWAYS:
- The Fund has raised $25.40 million comprising $19.05 million of third party capital (75 per cent) and $6.35 million of co-investment from Folkestone (25 per cent).
- The Fund has an 80 per cent interest in a circa 42.2-hectare residential land subdivision known as Amber in Wollert.
- Amber is located in Melbourne’s northern growth corridor.
- The Fund will develop, in joint venture with ID-Land (20 per cent of the Project), approximately 560 residential lots providing a selection of lot sizes and price points to suit a range of buyers.
Folkestone’s Managing Director, Mr Greg Paramor said, “the success of the capital raising demonstrates investors’ appetite for quality real estate investments. The strong pre-sales we have achieved to date, its location in one of Australia’s fastest growing areas, the forecast internal rate of return of 17.0 per cent and return on equity of 56.0 per cent (pre-tax, post fees) all contributed to the attractiveness of the Fund offer to our investor base.”
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
